Cariprazine in Children with Bipolar Disorder
Phase 3
380
about 5.9 years
10–17
68 sites in AR, CA, FL +13
About this study
Researchers are testing cariprazine, a treatment, to see if it helps children (ages 10-17) with bipolar I disorder who are experiencing depressive episodes. The trial will last for about 2 years and involve around 380 participants. Participants will receive either cariprazine or a placebo, and their response to the treatment will be monitored through regular visits and assessments.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cariprazine
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cariprazine
oral (Oral Capsule)
Primary: Abnormal Change from Baseline in Vital Signs, Change From Baseline in Abnormal Involuntary Movement Scale (AIMS), Change From Baseline in Barnes Akathisia Rating Scale (BARS), Change From Baseline in Simpson-Angus Scale (SAS), Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS), Number of Participants with Adverse Events
Psychiatry / Mental Health